News | Oncology Related Products | May 06, 2016

Study Finds Breast Cancer Adjuvant Therapy Benefits Vary Over Time

Therapies completed years ago may not keep covering survivors

breast cancer, adjuvant therapy, clinical study, University of Texas Health Science Center

May 6, 2016 — After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy and endocrine drugs to reduce the risk of the cancer returning. It's been assumed that the treatment effects of these therapies remain constant over time, but a new study from the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio suggests the opposite is true.

The study, published in the Journal of the National Cancer Institute, looked at 19 breast cancer adjuvant therapy clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Therapies were evaluated for relative benefit, defined as the percentage by which they reduced recurrence and death among study participants.

Researchers found time-varying treatment effects of adjuvant therapies in nearly half of the trials (nine of 19). "In some trials, the benefit diminished at specific points of time after surgery," said study senior author Ismail Jatoi, M.D., Ph.D., FACS. "In other trials, there was no benefit early on, but then there was a delayed benefit that emerged more than one year after surgery."

In one clinical trial, the researchers found that a regimen provided initial benefit, but then a subsequent disadvantage, to patients, he said. Jatoi is the Dale H. Dorn Chair in Surgery in the School of Medicine at the UT Health Science Center, and serves as professor and chief of the Division of Surgical Oncology and Endocrine Surgery.

The findings may change the way oncologists talk to their patients about effects of treatments they are receiving, Jatoi said.

"We are seeing more and more long-term survivors of breast cancer who had these treatments many years ago," he said. "The question is, if these treatment effects have waned, should we consider extended adjuvant treatment regimens for the long term in some patients."

Adjuvant therapy trials should be designed and interpreted with this in mind, he added.

In 2011, Jatoi wrote a viewpoint article published in the Journal of Clinical Oncology in which he proposed that treatment effects of adjuvant therapy regimens might vary over time. He approached the NSABP, one of the nation's largest clinical trials groups, about doing a study.

NSABP statisticians Hanna Bandos, Ph.D., and Jong Hyeon Jeong, Ph.D., conducted much of the work and are co-authors of the study.

For more information: www.jnci.oxfordjournals.org

Related Content

A patient prepares to have a tomosynthesis-guided prone breast biopsy using the Hologic Affirm prone biopsy system.

A patient prepares to have a tomosynthesis-guided prone breast biopsy using the Hologic Affirm prone biopsy system.

Feature | Breast Biopsy Systems | October 17, 2019 | By Harriet Borofsky, M.D.
The current body of research supporting...
Feature | Breast Imaging | October 16, 2019 | By Jeff Zagoudis
On Jan. 1, 2017, the U.S.
Genia Sutton, intGenia Sutton, interim director of radiology

Genia Sutton, interim director of radiology, has seen the benefit to patients. “Five minutes is a lot of time if you are thinking you may have breast cancer,” she said. “Now, technologists aren’t as rushed. They can give a more personal touch because they can spend more time with their patients.”

Sponsored Content | Case Study | Mammography | October 10, 2019
When Cullman Regional Medical Center in Alabama decided to
Hologic, Inc.’s Company’s Chairman, President and Chief Executive Officer Steve MacMillan, joined a number of employees to ring the Nasdaq Opening Bell for the 14th consecutive year on Oct. 2
News | Women's Health | October 04, 2019
Hologic, Inc.’s Company’s Chairman, President and Chief Executive Officer ...
Breast cancer awareness month is October
News | Clinical Case Studies | October 03, 2019
A decades-long decline in the breast cancer death rate continues, but has begun to slow in recent years, while breast
Volpara's breast density scale

Levels of breast density.

News | Women's Health | October 01, 2019
Celebrating its 10th Anniversary in 2019,...
University of Arizona to Develop New CT-Based Breast Cancer Diagnostic Imaging Method
News | Breast Imaging | September 27, 2019
Researchers at the University of Arizona Health Sciences are seeking a new and more accurate way to diagnose breast...
Partial and Whole-Breast Radiotherapy After Lumpectomy Provide Equally Satisfying Cosmetic Results
News | Radiation Therapy | September 25, 2019
Whole breast radiation and partial breast radiation following a lumpectomy yield similar cosmetic outcomes for women...
Discomfort May Deter Large Number of Women From Obtaining Mammograms
News | Mammography | September 25, 2019
Siemens Healthineers and national nonprofit HealthyWomen announced results from a new national survey designed to...
Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...